

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Ophthalmology

ESPS manuscript NO: 16150

Title: Clinical outcome of approved pharmacotherapy for macular edema secondary to branch retinal occlusion

Reviewer's code: 00505265

Reviewer's country: United States

Science editor: Xue-Mei Gong

Date sent for review: 2014-12-30 20:15

Date reviewed: 2015-01-07 03:36

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good		<input type="checkbox"/> Duplicate publication	
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input type="checkbox"/> Minor revision
	<input type="checkbox"/> Grade D: Rejected	BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

Good summary of recent clinical studies addressing BRVO treatments.

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Ophthalmology

ESPS manuscript NO: 16150

Title: Clinical outcome of approved pharmacotherapy for macular edema secondary to branch retinal occlusion

Reviewer's code: 00505119

Reviewer's country: Italy

Science editor: Xue-Mei Gong

Date sent for review: 2014-12-30 20:15

Date reviewed: 2015-01-01 17:06

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

The manuscript by Wang et al is a review article specific to macular edema in branch retinal vein occlusion. Some minor improvements can be made to the manuscript. 1) The title should be changed to show the nature of the study is a review because "clinical outcomes" gives the false impression of a clinical study 2) The authors confirm FDA approval of the treatment modalities but the European Medical Agency approval terms should also be mentioned as the World Journal of Ophthalmology has a broad diffusion 3) the complications of the treatment modalities are not sufficiently addressed: A) frequency of antiVEGF and complications, B) dexamethasone implants and IOP increase indicating specific times for clinical monitoring and C) migration of implant into the anterior chamber in patients with posterior capsule rupture etc. The information can be obtained from the following articles and it would be useful to cite these. Lambiase A et al. An update on intravitreal implants in use for eye disorders. Drugs of Today 2014; 50(3):239-249 Khurana RN et al. Dexamethasone implant anterior chamber migration. Ophthalmology 2014; 12(1):67

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Ophthalmology

ESPS manuscript NO: 16150

Title: Clinical outcome of approved pharmacotherapy for macular edema secondary to branch retinal occlusion

Reviewer's code: 00505049

Reviewer's country: China

Science editor: Xue-Mei Gong

Date sent for review: 2014-12-30 20:15

Date reviewed: 2015-01-02 19:23

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input checked="" type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good		<input type="checkbox"/> Duplicate publication	
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input type="checkbox"/> Minor revision
	<input type="checkbox"/> Grade D: Rejected	BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

This manuscript entitled "Clinical outcome of approved pharmacotherapy for macular edema secondary to branch retinal vein occlusion" was to review the treatment for macular edema secondary to branch retinal vein occlusion (BRVO) have approved by FDA of US. This is an interesting and well written. Major comments: 1) Title, I think author miss typing "vein" on branch retinal vein occlusion. 2) I think this is a kind of review paper for the treatment of BRVO, it is better to write clearly about how to select the articles by well randomized controlled trial or in recent 5 years. 3) There are three therapy approved by FDA of US.: Dexamethasone implants, Ranibizumab, and Aflibercept, I think if can have subtitle in manuscript will make it more clearly to read.